Replimune Group (NASDAQ:REPL) Given New $17.00 Price Target at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) had its target price boosted by stock analysts at JPMorgan Chase & Co. from $14.00 to $17.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 53.57% from the stock’s previous close.

A number of other equities analysts also recently issued reports on REPL. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Roth Mkm began coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. Barclays upped their price target on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Wedbush reissued an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a report on Thursday, June 6th. Finally, HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $16.80.

Replimune Group Price Performance

REPL opened at $11.07 on Tuesday. The company’s 50-day simple moving average is $10.29 and its two-hundred day simple moving average is $8.48. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The stock has a market capitalization of $756.30 million, a P/E ratio of -3.42 and a beta of 1.22. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.14.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. As a group, analysts predict that Replimune Group will post -3.11 EPS for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently bought and sold shares of REPL. Nisa Investment Advisors LLC lifted its position in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares in the last quarter. Point72 DIFC Ltd bought a new stake in Replimune Group during the 2nd quarter valued at approximately $57,000. Quest Partners LLC purchased a new position in Replimune Group in the 4th quarter worth approximately $76,000. Diversified Trust Co bought a new position in Replimune Group in the 1st quarter worth approximately $94,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Replimune Group by 72.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after purchasing an additional 4,975 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.